Nephrologist, Hong Kong. Interested in PD and Onconephrology. Alumnus @MSKCancerCenter. Tweets/retweets my own.
香港
Joined May 2020
- Tweets65
- Following188
- Followers80
- Likes1.2K
Will Pak retweeted
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy onlinelibrary.wiley.com/doi/… @kdjhaveri @Northwell_Med @ShrutiGkidney @AjHematology @onconephsociety @MGBKidneys @MayoClinicNeph
Happy to share our centre’s experience with Stenotrophomonas PD-related peritonitis. While uncommon, rates of relapse, catheter removal and peritonitis-associated deaths are significant. We discussed the treatment strategies according to our cohort and latest guidelines.
A 20-year single-centre case series of Stenotrophomonas maltophilia PD-related peritonitis in Hong Kong: 28 episodes in 27 patients, 21.4% medical cure, 28.6% peritonitis-associated death.
#PDI #PeritonealDialysis #ISPD
pubmed.ncbi.nlm.nih.gov/4284…
Will Pak retweeted
Here’s the ASN Onconephrology Program at #KidneyWeek 2026 in Denver.
A full day covering new therapies, kidney complications of cancer treatment, transplant, pathology, immunotherapy, & case-based discussions.
Hope to see many of you there!
@onconeph @rc_oncneph @SheronLatcha
Will Pak retweeted
Recommendations for the Management of Anemia in Patients with Cancer and Chronic Kidney Disease: A Position Statement from the American Society of Onco-Nephrology (ASON) - Kidney International kidney-international.org/art… @onconephsociety
Will Pak retweeted
Excited to share our review in @NatRevUrol “Urolithiasis in Patients with Cancer” @arihakimi
We discuss unique mechanisms driving stone disease in cancer patients, bidirectional relationship between cancer & urolithiasis, management of urolithiasis in this pt population
pubmed.ncbi.nlm.nih.gov/4233…
Will Pak retweeted
Presented at #ERA26:
In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: nej.md/4dZsVPD
@ERAkidney
ALT A line graph from an article published in the New England Journal of Medicine compares obinutuzumab and tacrolimus in treating primary membranous nephropathy over 104 weeks. The y-axis represents the percentage of patients relapse‑free, while the x-axis represents weeks. The graph shows two lines, one for obinutuzumab and another for tacrolimus. The image mentions the European Renal Association Congress at the top.
Will Pak retweeted
Amazing event not to miss! Zoom link in the invite @onconephsociety
Don’t miss the upcoming @onconephsociety educational seminar on MGRS and PGNMID.
Friday, May 22, 12 PM EDT 2026.
Will Pak retweeted
Tweetorial on Histotripsy related AKI @renalmyeloma @HofstraKidney
1) What is histotripsy? Histotripsy is a non-invasive, FDA-approved (as of late 2023) cancer treatment that uses focused ultrasound waves to destroy liver tumors without incisions, radiation, or chemotherapy.pmc.ncbi.nlm.nih.gov/article… @onconephsociety
Will Pak retweeted
Pls join us on @onconephsociety educational series on one of the hot topics
“ T cell mediated therapies in MM and Amyloidosis”
🛑April 24th 2026 12 pm EDT
Presented by Dr Nadia Al Haddad and Dr David Ortiz-Melo
Will Pak retweeted
What we know about the current perspectives of using bispecific antibodies in Glomerular Diseases @kdjhaveri @asnpublications
Journal of the American Society of Nephrology @KDJhaveri @asnpublications journals.lww.com/jasn/citati…
Will Pak retweeted
Single-center perspective of glomerular pathology in checkpoint inhibitor-treated patients
@Arjun_Mohan1 @MPAlexanderMD @HerrmannMd @KIReports
kireports.org/article/S2468-…
Will Pak retweeted
Pls join us for an amazing conference on Multiple Myeloma and Kidney Transplantation:Best Practices, Challenges and Future Directions
✅ March 20th 2026, 12PM EST
@itunuowoyemi
✅Dr. Owoyemi and Dr. Ziolkowski
Will Pak retweeted
For the first time @ISNWCN is organizing an onconephrology not to be missed with outstanding global speakers #ISNWCN privileged to have as co-chairs of this course @kdjhaveri @PepaSolerR
Will Pak retweeted
🌟🌟Upcoming is a great session on Diagnosing and managing ICI nephrotoxicity and GFR Assessment in patients with cancer - Insights from ASON position statements
💥ISN-ASON joint webinar
💥November 18th 1 pm CET
@PAmarapurkar @HerrmannMd @onconeph @ISNkidneycare
Will Pak retweeted
🎥Watch Dr Daniel Tak Mao Chan present the NDT publication:
Chronic Kidney Disease G3-5 in Lupus Nephritis- Prevalence, Progression, and Risk Factors
oup.cloud.panopto.eu/Panopto…
Will Pak retweeted
KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int.
Read the Guideline in KI: kdigo.co/KDIGO-IgAN-IgAV-Gui…
Download the Executive Summary: kdigo.co/IgAN-IgAV-Guideline…
Read the News Release: kdigo.co/KDIGO-IgAN-IgAV-Gui…
Co-chaired by Dr. Jürgen Floege (DE) and @BradRovin, this update to the 2021 KDIGO Glomerular Diseases Guideline on IgAN incorporates evidence through August 2024. Given the rapid pace of discovery, KDIGO will continue to update the guideline regularly so clinicians and patients have access to the latest science and recommendations.
“This guideline represents a fundamental shift in how we approach IgA nephropathy,” said Dr. Floege. “For the first time, we can target both the immune mechanisms driving IgA injury and the kidney’s maladaptive responses. This dual strategy offers a roadmap to slow progression and extend kidney survival in ways not possible just a few years ago.”
“The science is moving faster than ever, and the treatment landscape has changed dramatically,” said Dr. Rovin. “With therapies like targeted-release budesonide, sparsentan, and SGLT2 inhibitors, we can intervene earlier and tailor care. We are moving from a single approach to a toolkit of therapies that can truly change outcomes for people around the world."
Download the Guideline: kdigo.co/KDIGO-IgAN-IgAV-Gui…
Will Pak retweeted
The latest 2025 #Hypertension Guidelines are out 📣
#Nephpearls
📌 Use of risk-based thresholds for initiation of BP treatment
📌 BP thresholds and recommendations for treatment and follow-up
📌 Screening for features suggesting secondary hypertension
👉🏼 pubmed.ncbi.nlm.nih.gov/4081…
Will Pak retweeted
The Mayo MGRS Prediction Tool calculates the risk of finding monoclonal gammopathy of renal significance in a kidney biopsy in patients with monoclonal gammopathy - Kidney International @basmeomeo @fervenzafernan1 @SethiRenalPath kidney-international.org/art…
